Heparin concentration is critical for cell culture with human platelet lysate
Tài liệu tham khảo
Salem, 2010, Mesenchymal stromal cells: current understanding and clinical status, Stem Cells, 28, 585, 10.1002/stem.269
Sensebe, 2009, Mesenchymal stem cells for clinical application, Vox Sang, 98, 93, 10.1111/j.1423-0410.2009.01227.x
Jung, 2010, Identification of growth and attachment factors for the serum-free isolation and expansion of human mesenchymal stromal cells, Cytotherapy, 12, 637, 10.3109/14653249.2010.495113
Doucet, 2005, Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications, J Cell Physiol, 205, 228, 10.1002/jcp.20391
Schallmoser, 2007, Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells, Transfusion, 47, 1436, 10.1111/j.1537-2995.2007.01220.x
Fekete, 2012, Cytotherapy, 14, 540, 10.3109/14653249.2012.655420
Fekete, 2012, GMP-compliant isolation and large-scale expansion of bone marrow-derived MSC, PLoS One, 7, e43255, 10.1371/journal.pone.0043255
Kinzebach, 2013, Expansion of mesenchymal stem/stromal cells under xenogenic-free culture conditions, Adv Biochem Eng Biotechnol, 129, 33
Capelli, 2007, Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts, Bone Marrow Transplant, 40, 785, 10.1038/sj.bmt.1705798
Avanzini, 2009, Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors, Haematologica, 94, 1649, 10.3324/haematol.2009.006171
Holzwarth, 2010, Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells, BMC Cell Biol, 11, 11, 10.1186/1471-2121-11-11
Muller, 2006, Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM, Cytotherapy, 8, 437, 10.1080/14653240600920782
Lohmann, 2012, Donor age of human platelet lysate affects proliferation and differentiation of mesenchymal stem cells, PLoS One, 7, e37839, 10.1371/journal.pone.0037839
Cholewa, 2011, Expansion of adipose mesenchymal stromal cells is affected by human platelet lysate and plating density, Cell Transplant, 20, 1409, 10.3727/096368910X557218
Bieback, 2009, Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow, Stem Cells, 27, 2331, 10.1002/stem.139
Horn, 2010, Comparison of individual platelet lysates for isolation of human mesenchymal stromal cells, Cytotherapy, 12, 888, 10.3109/14653249.2010.501788
Schallmoser, 2009, Preparation of pooled human platelet lysate (pHPL) as an efficient supplement for animal serum-free human stem cell cultures, J Vis Exp, 32, 1
Walenda, 2012, Human platelet lysate gel provides a novel 3D-matrix for enhanced culture expansion of mesenchymal stromal cells, Tissue Eng Part C Methods, 18, 924, 10.1089/ten.tec.2011.0541
Andersen, 2004, Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery, Semin Thromb Hemost, 30, 609, 10.1055/s-2004-861502
Hofmann, 2004, Clinical application of enoxaparin, Expert Rev Cardiovasc Ther, 2, 321, 10.1586/14779072.2.3.321
Simonneau, 2006, A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer, J Thromb Haemost, 4, 1693, 10.1111/j.1538-7836.2006.02083.x
Marincola, 1987, Inhibition of activation of lymphokine-activated killer cells in vitro by the heparin preservative benzyl alcohol, Lancet, 2, 399, 10.1016/S0140-6736(87)92422-6
Walker, 2002, Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies, Br J Anaesth, 88, 848, 10.1093/bja/88.6.848
Tiozzo, 1991, Effect of heparin derived fractions on the proliferation and protein synthesis of cells in culture, Thromb Res, 62, 177, 10.1016/0049-3848(91)90191-X
Yoneda, 1988, Hyaluronic acid modulates proliferation of mouse dermal fibroblasts in culture, J Cell Sci, 90, 265, 10.1242/jcs.90.2.265
Koch, 2013, Pluripotent stem cells escape from senescence-associated DNA methylation changes, Genome Res, 23, 248, 10.1101/gr.141945.112
Schellenberg, 2012, Population dynamics of mesenchymal stromal cells during culture expansion, Cytotherapy, 14, 401, 10.3109/14653249.2011.640669
Schellenberg, 2013, Tracking of replicative senescence in mesenchymal stem cells by colony-forming unit frequency, Methods Mol Biol, 976, 143, 10.1007/978-1-62703-317-6_11
Marques-Gallego, 2010, Accurate non-invasive image-based cytotoxicity assays for cultured cells, BMC Biotechnol, 10, 43, 10.1186/1472-6750-10-43
Papathanasopoulos, 2011, Effects of antithrombotic drugs fondaparinux and tinzaparin on in vitro proliferation and osteogenic and chondrogenic differentiation of bone-derived mesenchymal stem cells, J Orthop Res, 29, 1327, 10.1002/jor.21405
Ho, 2008, Heterogeneity of mesenchymal stromal cell preparations, Cytotherapy, 10, 320, 10.1080/14653240802217011
Dominici, 2006, Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement, Cytotherapy, 8, 315, 10.1080/14653240600855905
Schallmoser, 2008, Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum, Tissue Eng Part C Methods, 14, 185, 10.1089/ten.tec.2008.0060
Schallmoser, 2013, Generation of a pool of human platelet lysate and efficient use in cell culture, Methods Mol Biol, 946, 349, 10.1007/978-1-62703-128-8_22
Matziolis, 2003, Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts, Calcif Tissue Int, 73, 370, 10.1007/s00223-002-2091-5
Hausser, 2004, Low doses and high doses of heparin have different effects on osteoblast-like Saos-2 cells in vitro, J Cell Biochem, 91, 1062, 10.1002/jcb.20007
Spivak-Kroizman, 1994, Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation, Cell, 79, 1015, 10.1016/0092-8674(94)90032-9
Handschin, 2005, Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro, Br J Surg, 92, 177, 10.1002/bjs.4809
Rajgopal, 2008, The effects of heparin and low molecular weight heparins on bone, Thromb Res, 122, 293, 10.1016/j.thromres.2006.10.025
Muir, 1997, A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats, Blood, 89, 3236, 10.1182/blood.V89.9.3236
Sivakumaran, 1996, Osteoporosis and vertebral collapse following low-dose, low molecular weight heparin therapy in a young patient, Clin Lab Haematol, 18, 55, 10.1111/j.1365-2257.1996.tb00741.x
Folwarczna, 2005, Effects of standard heparin and low-molecular-weight heparins on the formation of murine osteoclasts in vitro, Pharmacol Rep, 57, 635
Luo, 2008, Disruption of cell-matrix interactions by heparin enhances mesenchymal progenitor adipocyte differentiation, Exp Cell Res, 314, 3382, 10.1016/j.yexcr.2008.07.003
Mathews, 2012, Glycosaminoglycans enhance osteoblast differentiation of bone marrow derived human mesenchymal stem cells, J Tissue Eng Regen Med, 10.1002/term.1507
Eriksson, 2008, Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty, N Engl J Med, 358, 2765, 10.1056/NEJMoa0800374
Di, 2005, Direct thrombin inhibitors, N Engl J Med, 353, 1028, 10.1056/NEJMra044440
Bonin, 2009, Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium, Bone Marrow Transplant, 43, 245, 10.1038/bmt.2008.316
Osip, 2004, Differential effects of heparin and low molecular weight heparin on osteoblastogenesis and adipogenesis in vitro, Thromb Haemost, 92, 803, 10.1160/TH04-03-0199